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Acute respiratory infections are the leading infectious 
cause of death in both adults and children.1 The main 
pathogen responsible for this mortality is the pneumococcus, 
Streptococcus pneumoniae, and its treatment is complicated by 
the evolution of resistance to antibiotics. The first description 
of fully penicillin-resistant and multiply-resistant pneumococci 
was made by Professor Hendrik Koornhof  and his colleagues 
at Baragwanath Hospital, Soweto, South Africa and reported 
in the New England Journal of Medicine in 1978.2 These multiply-
resistant strains were nosocomial in origin and were restricted 
initially to infections among hospitalised children. Over the 
intervening 25 years, multiply-resistant strains developed a 
global distribution3 and there is almost no place on earth where 
the management of pneumococcal infections in both children 
and adults does not need to take into account the possibility of 
antimicrobial resistance. This review of the factors underlying 
that global expansion of resistant strains is dedicated to 
Hendrik Koornhof, my mentor, and the mentor of a generation 
of South African clinical microbiologists.
Age
Pneumococci resistant to beta-lactams and macrolides occur 
more frequently among children than adults,4-6 reflecting 
both the prolonged duration of carriage of pneumococci in 
children compared with adults7 and the greater per capita 
use of  antibiotics in children compared with adults. The 
exception to the association of young age with resistance in 
the pneumococcus is resistance to fluoroquinolones. This 
class of agent is not licensed for use in children, except for 
exceptional circumstances. Given that the burden of use to 
treat pneumococcal infections is in elderly adults, it is not 
surprising that this resistance emerged in the elderly8 and is 
associated with nosocomial exposures to fluoroquinolones 
in older patients with exacerbations of chronic bronchitis.9 
Fluoroquinolone-resistant pneumococci are also more common 
in elderly persons living in long-term care facilities.10 
Site of specimen
Resistance is more common in isolates from the respiratory 
tract,4 rather than from  invasive disease specimens such as 
blood or cerebrospinal fluid (CSF). This reflects both the likely 
selection of resistant strains in the nasopharynx, where there 
is a high density of organisms and antibiotic concentrations 
tend to be low, and a bias towards the collection of respiratory 
specimens only after initial treatments have failed. Respiratory 
specimens therefore mainly follow previous antibiotic 
therapy. A similar bias may allow resistant strains to be found 
more often in blood than CSF,5 as previous exposure to oral 
antibiotics may clear susceptible strains from blood, thus 
increasing the proportion of resistant strains, whereas previous 
antibiotics are less likely to eradicate susceptible strains from 
the CSF. 
Hospitalisation
Nosocomial acquisition is an important risk for the selection of 
resistant pneumococci,2,4,9 as is exposure to a nursing home.9,10 
Urban versus rural
The carriage of resistant strains was compared between 
a cluster randomised sample of children in rural Lesotho 
villages, some accessible only by  donkey, and similarly 
aged children from Maseru, the capital.11 Both penicillin and 
tetracycline resistance were significantly higher in urban 
versus rural children, probably due to significantly increased 
exposure of the urban children to recent antibiotic use (OR 8.8, 
p<0.01); past hospitalisation (OR 24.8, p<0.001); and more day 
care attendance (OR 13.1, p<0.001). These factors outweighed 
crowding, which was less common in the urban setting with 
significantly less children <5 years of age in the household (OR 
0.4, p<0.001).11 
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Streptococcus pneumoniae (the pneumococcus) is the leading 
vaccine-preventable cause of death in children and adults. 
The management of pneumococcal infections is complicated 
by the development of resistance to antimicrobials. Risk 
factors for increased resistance include young age, isolation 
from the upper respiratory tract, hospitalisation, residence 
in an urban area, day care attendance, previous exposure 
to antibiotics, female gender, exposure to specific serotypes 
and clones, HIV infection and exposure to a class of drug to 
which resistance can be easily selected from a susceptible 
population of organisms. Conjugate pneumococcal vaccine 
affords protection from resistant strains belonging to vaccine 
serotypes, but resistance is emerging in non-vaccine types.
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Day care
Day care is a significant risk for selection of resistant strains 
in both developing11 and developed12 country settings due to 
crowding and lack of hygiene that facilitate spread, as well as 
increased exposure to antibiotics which facilitate selection of 
resistant strains. Multiresistant pneumococcal clones have been 
shown to spread more quickly and to colonise more children in 
day care than do susceptible pneumococcal clones.13
Antibiotic use
By far the most important risk for antimicrobial resistance 
in the pneumococcus is exposure to antibiotic use. This has 
been demonstrated at the country level where there is a clear 
association of pneumococcal resistance with antibiotic use in 
the countries of the European Union;14 at county level where 
resistance has been correlated with use within counties in 
Iceland;15 and at the level of the individual where resistance 
associated with individual exposure has been known since 
the early 1980s.16 The duration of increased risk has been 
demonstrated to be similar to the duration of carriage of 
pneumococci, i.e. 2 - 7 weeks.15 The relationship between 
antimicrobial resistance and exposure is complicated by the 
emergence of multiply-resistant pneumococci that may be 
selected by several classes of antibiotics. Modelling suggests 
that strains resistant to multiple classes of antibiotics have 
spread at the expense of both susceptible strains and those 
resistant only to one class17 and it has been shown that certain 
drugs, such as azithromycin, which has a long half-life, may 
be more important in the selection of multiply-resistant strains 
than may drugs from other classes of antimicrobial agent.18 
Not only do antibiotics of various classes select for resistance, 
but drugs directed against similar targets in unrelated species, 
such as the malaria parasite, may lead to resistance in the 
pneumococcus. Fansidar, which acts to inhibit folate synthesis 
in falciparum, may select for pneumococci resistant to folate 
antagonists, and such selection has been documented among 
children receiving the drug in Malawi.19 Duration of use and 
dose as risks for resistance in the pneumococcus have been 
examined in only two studies to date, one retrospective20 
and one prospective,21 both concluding that short duration 
and higher dose select less for resistance than do longer 
durations of exposure and lower doses.  Although both 
appropriate and inappropriate antibiotic use may select for 
resistance, inappropriate use (e.g. to treat upper respiratory 
viral infections) may exceed appropriate use in many settings 
and the large differences in pneumococcal resistance found in 
Germany (less resistance) versus France (more resistance) have 
been suggested to reflect, at least in part, the frequency with 
which inappropriate antibiotic use for respiratory indications 
occurs in France22 compared with Germany.
Gender
Although pneumococcal disease has a male predominance 
among adults in Soweto, it has been shown that females 
have more resistant pneumococcal infections than men,23 
probably related to their increased exposure to resistant strains 
transmitted from children.
Serotype
The so-called ‘paediatric serotypes’ of pneumococci are 
the strains commonly found in children, and these strains 
are carried in the nasopharynx for longer times than other 
serotypes.7 These types are more resistant to antibiotics than 
are types more often found in adults, which are less often to be 
found in carriage.24,25
Clones
Within the capsular types of pneumococci there are a number 
of antibiotic-resistant pneumococcal clones that have spread 
globally.26 These strains have over the past 29 years become 
the dominant pneumococci isolated from invasive infections 
in most developed countries and are documented by a 
collaboration of scientists called the Pneumococcal Molecular 
Epidemiology Network (PMEN) (http://www.sph.emory.
edu/PMEN/). The preponderance of these global clones 
can be considerable, and an analysis of the clonality of 
invasive pneumococci fully resistant to penicillin, before the 
introduction of pneumococcal conjugate vaccine in the USA, 
showed that 93% of these invasive strains belonged to just 
eight clones, of which five were PMEN global clones.27
HIV
The antibiotic-resistant pneumococcus is more commonly 
found among both children and adults infected with HIV 
than among those who are HIV-uninfected.23,28 This reflects 
a number of risk factors including increased hospitalisation, 
increased infections with paediatric pneumococcal serogroups 
and increased exposure to antibiotics, not only therapeutically, 
but also prophylactically29 among HIV-infected people. 
Mechanism of resistance – ease of 
selection
A review of mechanisms of resistance to antimicrobials is 
beyond the scope of this article, but certain mechanisms may 
facilitate selection of resistance above others. Resistance to 
beta-lactam antibiotics requires multiple step-wise mutations 
in the genes encoding penicillin-binding proteins; resistance 
to macrolides is usually due to acquisition of exogenous efflux 
or methylating enzymes, but only rarely due to mutations 
in ribosomal proteins or ribosomal RNA; and resistance to 
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fluoroquinolones requires at least two step-wise mutations 
in the topo-isomerase genes. Once the resistance genes are 
acquired, antibiotic use may select resistant strains, but ease 
of initial selection from a susceptible population depends on 
the frequency with which resistant strains can arise from the 
susceptible population. Resistance to the classes mentioned 
above rarely arises from susceptible strains and dissemination 
requires pre-existing resistant strains. Pre-existing first-step 
fluoroquinolone mutants may therefore be a significant risk 
for the evolution of subsequent fully resistant strains in long-
term care facilities.30 The most common resistance determinant 
in the pneumococcus globally, however, is resistance to 
trimethoprim-sulphamethoxazole (TMP-SMZ), and this 
resistance can be selected  with a high frequency (in >30% 
of exposed individuals after a week of exposure).19 A factor 
in the frequency of the selection of this resistance is that it is 
conferred by just a single nucleotide base change in the gene 
encoding dihydrofolate reductase,31 and can thus be selected 
with ease from susceptible populations of  >107 pneumococci. 
Although TMP-SMZ is less often used these days to treat 
pneumococcal infections, its widespread use as prophylaxis 
in HIV-infected children and adults represents a significant 
risk for selection of resistance. Of particular concern is the 
observation that TMP-SMZ use was the most significant risk 
for penicillin-resistant pneumococci in an African setting in 
which strains resistant to both drugs were common.32
Vaccine impact
In contrast to the factors above that all contribute to an increase 
in resistance, the introduction of conjugate pneumococcal 
vaccine in children, directed against the paediatric serotypes 
that included most of the serotypes associated with resistance, 
has been, at least initially, associated with a reduction in 
resistance. Pneumococcal polysaccharide conjugated to 
diphtheria cross-reacting molecule (CRM) prevents the 
acquisition of antibiotic-resistant strains belonging to vaccine 
serotypes33-35 and has been shown to reduce resistant infections 
among vaccinated children in a prospective randomised trial.36 
Effectiveness studies in the USA demonstrated the reduction 
in antibiotic resistance in invasive pneumococcal infections 
after introduction of conjugate vaccine, not only in children 
but also in adults due to herd immunity.37-39 Unfortunately,  in 
isolates from the respiratory tract it has quickly become evident 
that continuing antibiotic use is selecting resistance in non-
vaccine isolates.40 This meant that little impact on resistance 
was found in nasopharyngeal isolates41,42 or ear isolates43 after 
vaccination. Recently there has been a significant expansion 
of antibiotic-resistant invasive serotype 19A infections after 
vaccine licensure in the USA.44-47 It is clear therefore that 
continuing exposure to antibiotics in the post-vaccine era 
will result in expansion of resistance among non-vaccine 
serotypes. The relative contributions of vaccination to reduce 
resistance, and antibiotic to increase resistance, have been 
studied in children attending day care in France. Children at 
lowest risk of resistant strains (vaccinated and with no recent 
antibiotic exposure) had only 4% carriage of penicillin-resistant 
pneumococci, compared with 16% carriage of resistant strains 
among those at high risk (not vaccinated and recently received 
antibiotics).48
Conclusions  
Multiple risks exist for the selection and dissemination of 
antibiotic-resistant pneumococci. These risks have led to the 
global dissemination of multiply-resistant pneumococcal 
clones, particularly, but not exclusively among children. 
Most of the risk factors for resistance have a common thread, 
namely exposure to the antibiotic to which the pneumococcus 
is resistant. Conjugate pneumococcal vaccine dramatically 
reduced resistance among invasive pneumococci after its 
introduction, but resistance is emerging in non-vaccine types 
and the continued selective advantage of resistance in the 
presence of antibiotic may overwhelm the vaccine impact on 
resistance in the future. 
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